JP7803924B2 - 造血幹細胞移植によって引き起こされる移植片対宿主病を治療する方法 - Google Patents

造血幹細胞移植によって引き起こされる移植片対宿主病を治療する方法

Info

Publication number
JP7803924B2
JP7803924B2 JP2023504356A JP2023504356A JP7803924B2 JP 7803924 B2 JP7803924 B2 JP 7803924B2 JP 2023504356 A JP2023504356 A JP 2023504356A JP 2023504356 A JP2023504356 A JP 2023504356A JP 7803924 B2 JP7803924 B2 JP 7803924B2
Authority
JP
Japan
Prior art keywords
body weight
days
compound
pharmaceutical composition
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023504356A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023535035A (ja
JPWO2022017412A5 (https=
JP2023535035A5 (https=
Inventor
チャンリン チェン，
ヤンピン チャオ，
ホンジュン ワン，
ウェイティン チョン，
ジン リ，
ジン チャオ，
ウェイナ リウ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Tide Pharmaceutical Co Ltd
Original Assignee
Beijing Tide Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Tide Pharmaceutical Co Ltd filed Critical Beijing Tide Pharmaceutical Co Ltd
Publication of JP2023535035A publication Critical patent/JP2023535035A/ja
Publication of JPWO2022017412A5 publication Critical patent/JPWO2022017412A5/ja
Publication of JP2023535035A5 publication Critical patent/JP2023535035A5/ja
Application granted granted Critical
Publication of JP7803924B2 publication Critical patent/JP7803924B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2023504356A 2020-07-22 2021-07-21 造血幹細胞移植によって引き起こされる移植片対宿主病を治療する方法 Active JP7803924B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010713637 2020-07-22
CN202010713637.0 2020-07-22
PCT/CN2021/107575 WO2022017412A1 (zh) 2020-07-22 2021-07-21 治疗造血干细胞移植后的移植物抗宿主病的方法

Publications (4)

Publication Number Publication Date
JP2023535035A JP2023535035A (ja) 2023-08-15
JPWO2022017412A5 JPWO2022017412A5 (https=) 2024-07-29
JP2023535035A5 JP2023535035A5 (https=) 2024-07-29
JP7803924B2 true JP7803924B2 (ja) 2026-01-21

Family

ID=79728482

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023504356A Active JP7803924B2 (ja) 2020-07-22 2021-07-21 造血幹細胞移植によって引き起こされる移植片対宿主病を治療する方法

Country Status (11)

Country Link
US (1) US20230285393A1 (https=)
EP (1) EP4186508A4 (https=)
JP (1) JP7803924B2 (https=)
KR (1) KR20230043891A (https=)
CN (2) CN121846099A (https=)
AU (1) AU2021313124A1 (https=)
BR (1) BR112023001049A2 (https=)
CA (1) CA3186564A1 (https=)
IL (1) IL299985A (https=)
TW (2) TW202216691A (https=)
WO (1) WO2022017412A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL311447A (en) * 2021-09-18 2024-05-01 Beijing Tide Pharmaceutical Co Ltd A solid form of a Rho-linked protein kinase inhibitor or a solvate thereof, a method of preparation and use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190010143A1 (en) 2017-06-30 2019-01-10 Beijing Tide Pharmaceutical Co., Ltd. Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof
US20190276440A1 (en) 2017-06-30 2019-09-12 Beijing Tide Pharmaceutical Co., Ltd. Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120202793A1 (en) * 2009-03-09 2012-08-09 Paul Sweetnam Rho kinase inhibitors
CN113620933A (zh) * 2012-10-05 2021-11-09 卡德门企业有限公司 Rho激酶抑制剂
WO2018039539A1 (en) * 2016-08-26 2018-03-01 Lycera Corporation Indazolyl-l,2,4-thiadiazolamines and related compounds for inhibition of rho-associated protein kinase and the treatment of disease
US10323023B2 (en) * 2017-06-30 2019-06-18 Beijing Tide Pharmaceutical Co., Ltd. Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof
TWI818919B (zh) * 2017-08-15 2023-10-21 美商歐米諾斯公司 用於治療和／ 或預防與造血幹細胞移植有關的移植物抗宿主病和／ 或瀰漫性肺泡出血和／ 或靜脈閉塞性病的方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190010143A1 (en) 2017-06-30 2019-01-10 Beijing Tide Pharmaceutical Co., Ltd. Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof
US20190276440A1 (en) 2017-06-30 2019-09-12 Beijing Tide Pharmaceutical Co., Ltd. Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BLOOD，2016年，Vol.127, No.17，pp.2144-2154

Also Published As

Publication number Publication date
JP2023535035A (ja) 2023-08-15
EP4186508A1 (en) 2023-05-31
TW202216691A (zh) 2022-05-01
IL299985A (en) 2023-03-01
KR20230043891A (ko) 2023-03-31
CN116322670A (zh) 2023-06-23
WO2022017412A1 (zh) 2022-01-27
AU2021313124A1 (en) 2023-03-09
CN121846099A (zh) 2026-04-14
TWI868660B (zh) 2025-01-01
EP4186508A4 (en) 2024-10-16
US20230285393A1 (en) 2023-09-14
TW202327609A (zh) 2023-07-16
CA3186564A1 (en) 2022-01-27
BR112023001049A2 (pt) 2023-03-07

Similar Documents

Publication Publication Date Title
AU2020230574B2 (en) Method for treating fatty liver disease and/or steatohepatitis
US12582653B2 (en) Method for treating idiopathic pulmonary fibrosis
JP7803924B2 (ja) 造血幹細胞移植によって引き起こされる移植片対宿主病を治療する方法
JP7665529B2 (ja) ジアミノピリミジン化合物を使用することによって咳を治療する方法
HK40086216A (en) Method for treating graft versus host disease caused by hematopoietic stem cell transplantation
HK40058942A (en) Method for treating fatty liver disease and/or steatohepatitis
HK40064686A (en) Method for treating idiopathic pulmonary fibrosis
CN120025367A (zh) 一类磷酸烯醇化合物及其制备方法和在机体炎症性疾病中的应用
HK40062124A (en) Method for treating cough by using diaminopyrimidine compound
CN120774829A (zh) 一类氨基酸化合物及其在机体炎症性疾病中的用途
KR20250079218A (ko) 진폐증을 치료하는 방법
HK40063173A (en) Method for treating idiopathic pulmonary fibrosis
HK40054971B (zh) 治疗脂肪性肝病和/或脂肪性肝炎的方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240719

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240719

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250617

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251014

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260106

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260108

R150 Certificate of patent or registration of utility model

Ref document number: 7803924

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150